Edition:
United States

People: GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,475.50GBp
4:18am EST
Change (% chg)

15.50p (+1.06%)
Prev Close
1,460.00p
Open
1,466.00p
Day's High
1,479.00p
Day's Low
1,463.00p
Volume
840,590
Avg. Vol
9,228,947
52-wk High
1,745.56p
52-wk Low
1,259.32p

Redfern, David 

Mr. David Redfern is Chief Strategy Officer of GlaxoSmithKline PLC. He joined CET as Chief Strategy Officer in May 2008 and is responsible for corporate development and strategic planning. In addition, he was appointed Chairman of the Board of ViiV Healthcare Ltd. in April 2011 and a Non-Executive Director of the Aspen Pharmacare Ltd. Board in February 2015. Previously, he was Senior Vice President, Northern Europe with responsibility for GSK’s pharmaceutical businesses in that region and, prior to that, was Senior Vice President for Central and Eastern Europe. David joined GSK in 1994 and was Finance Director of the European business from 1999 to 2002. David has a Bachelor of Science degree from Bristol University in the UK and is a Chartered Accountant.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Philip Hampton

522,000

Andrew Witty

6,661,000

Simon Dingemans

3,166,000

Moncef Slaoui

7,324,000

Roger Connor

--

Abbas Hussain

--
As Of  30 Dec 2015